Publications
Jeanguenat H, Schnoz A, Amour A.K, Ahmada A.A, Seif S.N, Mohammed I.S, Hattendorf J, Ali S.M, Keiser J. Efficacy, safety, and acceptability of a child-friendly, chewable formulation of oxantel pamoate versus mebendazole for Trichuris spp infections in children aged 2-12 years in Tanzania: a randomised, single-blind, phase 2 trial. Lancet Infect Dis. 2026(in press). DOI: 10.1016/s1473-3099(26)00238-0
Schnoz A, Jeanguenat H, Msellem A.S, Mohammed I.S, Abdalla R.S, Seif S.N, Amour A.K, Khamis M.J, Mougeni F.L, Volotko O, Sieradzan O, Cheeseman K.D, Nyangweso G.M, Egondi T.W, Barreira F, Hübner M.P, Zehetmayer S, Ali S.M, Keiser J. Efficacy and safety of oxfendazole in adults with Trichuris spp. infection in Pemba Island, Tanzania: a double-blind, phase 2a, randomised controlled trial. eClinicalMedicine. 2026;101. DOI: 10.1016/j.eclinm.2026.104273
Journal Article
Taylor L, Many S, Jeanguenat H, Hattendorf J, Sayasone S, Keiser J. Efficacy and safety of ascending doses of emodepside in comparison with ivermectin in adults infected with Strongyloides stercoralis in Laos: a phase 2a, dose-ranging, randomised, parallel-group, placebo-controlled, single-blind clinical trial. Lancet Infect Dis. 2025;25(11):1254-1264. DOI: 10.1016/s1473-3099(25)00255-5
van Beek A.E, Jeanguenat H, Häberli C, Pouw R.B, Lamers C, Pál G, Gál P, Schmidt C.Q, Ricklin D, Keiser J. Praziquantel and factor H recruitment differentially affect the susceptibility of Schistosoma mansoni to complement-mediated damage. Front Immunol. 2024;15:1474358. DOI: 10.3389/fimmu.2024.1474358